Article

2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 74, n° 6
pages 1077-1085 (juin 2016)
Doi : 10.1016/j.jaad.2016.01.019
accepted : 13 January 2016
Original Articles

Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial
 

Gaël Deplanque, MD, PhD a, , Radj Gervais, MD b, Alain Vergnenegre, MD, PhD c, Lionel Falchero, MD d, Pierre-Jean Souquet, MD e, Jean-Michel Chavaillon, MD f, Bruno Taviot, MD g, Ghislaine Fraboulet, MD h, Hakim Saal, MD i, Caroline Robert, MD, PhD j, Olivier Chosidow, MD, PhD k
on behalf of

CYTAR investigators

a Swiss Cancer Center Lausanne, Lausanne, Switzerland 
b Centre Régional de Lutte Contre le Cancer Baclesse, Caen, France 
c Hopital Du Cluzeau, Limoges, France 
d Centre Hospitalier de Villefranche, Villefranche sur Saône, France 
e Centre Hospitalier Lyon-Sud, Pierre Bénite, France 
f Centre Hospitalier D'Antibes, Antibes, France 
g Centre Médical N. De Pontoux, Chalon Sur Saône, France 
h Centre Hospitalier René Dubos, Pontoise, France 
i Laboratoires Roche, Boulogne-Billancourt, France 
j Institut Gustave Roussy, Villejuif, France 
k Hôpital Henri Mondor, Créteil, France 

Reprint requests: Gaël Deplanque, MD, PhD, Département d'Oncologie, Service d'Oncologie Médicale, Bureau BH 09/737, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.Département d'OncologieService d'Oncologie MédicaleBureau BH 09/737, Rue du Bugnon 46LausanneCH-1011Switzerland
Abstract
Background

Rash is a common epidermal growth factor receptor inhibitor–induced toxicity that can impair quality of life and treatment compliance.

Objective

We sought to evaluate the efficacy of doxycycline in preventing erlotinib-induced rash (folliculitis) in patients with non-small-cell lung cancer.

Methods

This open-label, randomized, prospective, phase II trial was conducted in 147 patients with locally advanced or metastatic non-small-cell lung cancer progressing after first-line chemotherapy, randomized for 4 months with erlotinib alone 150 mg/d per os (control arm) or combined with doxycycline 100 mg/d (doxycycline arm). Incidence and severity of rash, compliance, survival, and safety were assessed.

Results

Baseline characteristics of the 147 patients were well balanced in the intent-to-treat population. Folliculitis occurred in 71% of patients in the doxycycline arm and 81% in the control arm (P  = .175). The severity of folliculitis and other skin lesions was lower in the doxycycline arm compared with the control arm. Other adverse events were reported at a similar frequency across arms. There was no significant difference in survival between treatment arms.

Limitations

The open-label design of the study and the duration of the treatment with doxycycline are limitations.

Conclusion

Doxycycline did not reduce the incidence of erlotinib-induced folliculitis, but significantly reduced its severity.

The full text of this article is available in PDF format.

Key words : doxycycline, erlotinib, folliculitis, non-small-cell lung cancer, rash

Abbreviations used : AE, CI, CONSORT, CTCAE, CYTAR, DI, ECOG, EGFR, NCI, NSCLC, OS, PFS, QoL, TEAE



 Supported by Roche.
 Disclosure: Dr Deplanque has received research funds from Roche. Mr Vergnenegre has received research funds from Chugai, Boehringer, Lilly, Roche, and AstraZeneca; and is a consultant for MSD, AstraZeneca, and Roche. Mr Souquet has received honoraria from Roche, Lilly, AstraZeneca, Pfizer, and Amgen. Mr Saal is a salaried employee of Roche. Ms Robert is a consultant for BMS, Roche, GSK, Merck, and Novartis. Mr Chosidow is a consultant for Roche. Mr Gervais, Mr Falchero, Mr Chavaillon, Mr Taviot, and Mr Fraboulet have no conflicts of interest to declare.



© 2016  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline